<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66945">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01661439</url>
  </required_header>
  <id_info>
    <org_study_id>PCTRPL</org_study_id>
    <secondary_id>preconceptional heparin in APS</secondary_id>
    <nct_id>NCT01661439</nct_id>
  </id_info>
  <brief_title>Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome</brief_title>
  <official_title>A Randomized Clinical Trial of Using Preconceptional Low Molecular Heparin AND OR Low Dose Asprin in Patient With Antiphospholipid Syndrome(APS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's Health University Hospital, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Woman's Health University Hospital, Egypt</source>
  <oversight_info>
    <authority>Egypt: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preconceptional use of low molecular weight heparin in patient with recurrent miscarriages
      with positive anti phospholipid antibodies increase the implantation rate and the duration
      of pregnancy with low complications to the mother and the baby.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preconceptional heparin during follicular or luteal phase,improves the implantation rate by
      increasing the blood flow and increasing the implantation factors,also decreasing the
      pregnancy complication resulting from  Antiphospholipid Syndrome (APS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Pregnancy continuation beyond twelve weeks gestation</measure>
    <time_frame>ONE YEAR</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>giving low molecular weight heparin in patients with positive anti phospholipid antibodies with history of recurrent miscarriages or intrauterine fetal deaths in the preconceptional period one month before pregnancy with follow up as regarding the clinical pregnancy rate,the rate of continuation of pregnancy beyond 28 weeks gestation and the complications related to long term use of heparin and the severity of complication of APS in comparison to the traditional use of anticoagulant after documentation of the fetal heart rate</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Recurrent Pregnancy Losses</condition>
  <condition>Positive Anti Phospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Low molecular weight heparin</arm_group_label>
    <description>SC LMWH IN patients with recurrent pregnancy loss</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low molecular weight heparin (enoxeparine)</intervention_name>
    <description>1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.</description>
    <arm_group_label>Low molecular weight heparin</arm_group_label>
    <other_name>clexane,innohep</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with recurrent pregnancy losses either two or more recurrent miscarriages or
        intrauterine fetal deathes after 20 weeks of gestation with positive antiphospholipid
        antibodies in medium to high titer in two occasions 6 weeks apart.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All women with recurrent first-trimester miscarriage and all women with one or more
             second-trimester miscarriage who screened before pregnancy for antiphospholipid
             antibodies.

          2. To diagnose antiphospholipid syndrome it is mandatory that the woman has two positive
             tests at least 12 weeks apart for either lupus anticoagulant or anticardiolipin
             antibodies of immunoglobulin G and/or immunoglobulin M class present in a medium or
             high titre over 40 g/l or ml/l,or above the 99th percentile).

        In the detection of lupus anticoagulant, the dilute Russell's viper venom time test
        together with a platelet neutralisation procedure is more sensitive and specific than
        either the activated partial thromboplastin time test or the kaolin clotting time test.
        Anticardiolipin antibodies are detected using a standardised enzyme linked immunosorbent
        assay.

        Exclusion Criteria:

          1. Age above forty years old .

          2. Intrauterine abnormalities (as assessed by ultrasound, hysterosonography,
             hysterosalpingogram, or hysteroscopy).

          3. Fibroids distorting uterine cavity .

          4. Abnormal parental karyotype .

          5. Other identifiable causes of recurrent miscarriages (tests initiated only if
             clinically indicated) e.g., diabetes, thyroid disease and systemic lupus
             erythematosus (SLE).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alaa Mahmoud Ismail, M.D</last_name>
    <phone>+201000459514</phone>
    <email>dr.alaa_ismail@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hassan salah Kamel, M.D</last_name>
    <phone>+201006623455</phone>
    <email>hkamelhkamel@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Women Health Hospital</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HASSAN S KAMEL, MD</last_name>
      <phone>+2010066436</phone>
      <email>hkamelhkamel@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Alaa M Ismail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 1, 2013</lastchanged_date>
  <firstreceived_date>July 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woman's Health University Hospital, Egypt</investigator_affiliation>
    <investigator_full_name>alaa eldeen mahmoud ismail</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Recurrent miscarriages</keyword>
  <keyword>recurrent pregnancy loss</keyword>
  <keyword>aps</keyword>
  <keyword>anti coagulants in pregnancy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
